Dermatol. praxi. 2007;1(4):188-190

Imiquimod in the therapy of skin diseases

MUDr. Helena Korandová CSc
Privátní kožní ambulance Olomouc

The goal of dermatology treatment with an appropriate medication is not to cause an adverse reaction, not to disrupt its integrity, and not to produce cosmetically unacceptable consequences. In the same time the treatment must be sufficiently effective, controlling the course of the disease over a prolonged period of time or preferably lead to the complete recovery. Thus it is necessary that the selected treatment is targeted on pathogenetic mechanisms of the disease. One of the modern external medications meeting the outlined criteria is imiquimod (Aldara 5% cream) due to its antiviral and antitumor effect.

Keywords: imiquimod, indication, actinic keratosis

Published: February 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Korandová H. Imiquimod in the therapy of skin diseases. Dermatol. praxi. 2007;1(4):188-190.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Al-Dujaili Z, Hsu S. Imiquimod- induced vitiligo. Dermatol.Online.J. 2007 May 1, 13(2): 10. Go to original source...
    2. Arican O. Topical treatment of molluscum contagiosum with imiquimod 5% cream in turkish children. Pediatr.Int. 2006 Aug, 48 (4): 403-405. Go to original source... Go to PubMed...
    3. Babel n, Eibl N, Ulrich C, et al. Development of Kaposi´s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl. Infect. Dis. 2007 Apr 11.
    4. Bertholt C, Dickerson MC, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER 2 mutation with imiquimod. J. Am. Acad. Dermatol. 2007 May, 56 (5): 882-886. Go to original source... Go to PubMed...
    5. Brodell LA, Mercurio MG, Brodell RT. The diagnosis and treatment of human papillomavirus-mediated genital lesions. Cutis 2007 Apr, 79 (4 Suppl): 5-10.
    6. Chang YC, Madkan V, et al. Current potential uses of imiquimod. South. Med. J. 2005 Sep, 98 (9): 852. Go to original source... Go to PubMed...
    7. Chiam LY, Chan YC. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Br. J. Dermatol. 2007 Mar, 156 (3): 560-562. Go to original source... Go to PubMed...
    8. Del Rosso Q. The treatment of viral infection and nonmelanoma skin cancers. Cutis 2007 Apr, 79 (4 Suppl): 29-35.
    9. El- On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Exp. Parasitol. 2007 Jun, 116 (2): 156-162. Go to original source... Go to PubMed...
    10. Goldenberg G, Krowchuk DP, Jorizzo JL. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% team. J. Dermatol. Treat. 2006, 17(2): 121-123. Go to original source... Go to PubMed...
    11. Gul V, Gonul M, et al. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv, Ther. 2006 Sep- Oct, 23(5): 787-792. Go to original source... Go to PubMed...
    12. Hadley G, Derdy S, Moore RA. Imiquimod for aktinic keratoses: systemic review and meta-analysis. J. Invest. Dermatol. 2006 Jun, 126(6): 1251-1255. Go to original source... Go to PubMed...
    13. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J. Am. Acad. Dermatol. 2007 Jan, 56(1): 63-68. Go to original source... Go to PubMed...
    14. Jones S, Kress D. Treatment od molluscum contagiosum and herpes simplex virus cutaneous infections. Cutis 2007 May l, 13(2): 10.
    15. Letada PR, Sparling JD, Norwood C. Imiquimod in the treatment of alopecia universalis. Cutis 2007 Feb, 79(2): 138-140. Go to PubMed...
    16. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morfea. Cutan. Med. Surg. 2004 May - Jun, 8(3): 166-169. Go to original source... Go to PubMed...
    17. Micali G, Nasca MR, De Pasquale R. Erythroplasia of Queyrat treated with imiquimod 5% cream. J. Am. Acad. Dermatol. 2006 Nov, 55(5): 901-903. Go to original source... Go to PubMed...
    18. Montes-De-Oca-Sanchez G, Tirado-Sanchez A, Garcia-Ramirez V. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. J. Dermatol. Treat. 2006, 17(5): 319-320. Go to original source... Go to PubMed...
    19. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br. J. Dermatol. 2006 Oct, 155(4): 653-656. Go to original source... Go to PubMed...
    20. Rosen T, Harting M, Gibson M. Treatment of Bowen´s dinase with topical 5% imiquimod cream: retrospective study. Dermatol. Surg. 2007 Apr, 33(4): 427-431, discussion 431-432. Go to original source... Go to PubMed...
    21. Slade HB, Owens ML, Tomai HA, Miller RL. Imiquimod 5% cream (Aldara). Expert Opin. Investig. Drugs. 1998 Mar, 7(3): 437-449. Go to original source... Go to PubMed...
    22. Torres A, Storey L, Anders H, et al. Immune- mediated ganges in actinic keratoses following topical treatment with imiquimod 5% cream. J. Transpl. Med. 2007 Jan, 26: 5-7. Go to original source... Go to PubMed...
    23. Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J. Dermatol. 2006 Aug, 47(3): 169-171. Go to original source... Go to PubMed...
    24. Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J. Am. Acad. Dermatol. 2006 Dec, 55(6): 1024-1031. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.